Kala Pharmaceuticals Faces Foreclosure and Leadership Changes

An announcement from Kala Pharmaceuticals ( (KALA) ) is now available.

On October 18, 2025, Kala Pharmaceuticals faced a significant financial setback as Oxford, a creditor, announced its intention to foreclose on all of the company’s remaining assets and restricted the use of cash to minimal payroll expenses. Consequently, on October 19, 2025, the board terminated all remaining employees not necessary for the foreclosure process, including the employment of President and CEO Todd Bazemore, who will remain as a director and principal executive officer. Oxford has taken control of the company’s cash resources, leaving Kala Pharmaceuticals unable to continue filing required reports with the SEC and anticipating delisting from The Nasdaq Capital Market. The company does not expect any distributions to stockholders or unsecured creditors following the foreclosure.

The most recent analyst rating on (KALA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Kala Pharmaceuticals stock, see the KALA Stock Forecast page.

Spark’s Take on KALA Stock

According to Spark, TipRanks’ AI Analyst, KALA is a Underperform.

Kala Pharmaceuticals faces significant financial difficulties, marked by declining revenues and heavy reliance on debt, which pose serious risks. The technical analysis reflects a strong downtrend, with the stock being oversold, adding to the negative outlook. Valuation is unattractive due to negative earnings and the lack of a dividend, further weighing down the stock’s appeal.

To see Spark’s full report on KALA stock, click here.

More about Kala Pharmaceuticals

Average Trading Volume: 1,023,500

Technical Sentiment Signal: Sell

Current Market Cap: $9.2M

See more insights into KALA stock on TipRanks’ Stock Analysis page.